[go: up one dir, main page]

CN113226336A - 一种在细胞中递送基因的方法 - Google Patents

一种在细胞中递送基因的方法 Download PDF

Info

Publication number
CN113226336A
CN113226336A CN201980083940.2A CN201980083940A CN113226336A CN 113226336 A CN113226336 A CN 113226336A CN 201980083940 A CN201980083940 A CN 201980083940A CN 113226336 A CN113226336 A CN 113226336A
Authority
CN
China
Prior art keywords
cells
cell
virus
protein
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980083940.2A
Other languages
English (en)
Other versions
CN113226336B (zh
Inventor
汪沛
贾璐盈
林彦妮
牛志杰
许丹
方姣龙
袁慧
刘婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cure Genetics Co ltd
Original Assignee
Cure Genetics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cure Genetics Co ltd filed Critical Cure Genetics Co ltd
Publication of CN113226336A publication Critical patent/CN113226336A/zh
Application granted granted Critical
Publication of CN113226336B publication Critical patent/CN113226336B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明涉及一种向靶细胞中递送基因的方法。本发明利用免疫细胞作为病毒包装以及运输的载体，完成细胞间生物大分子的递送，进而在靶细胞中改变其原有特性或是产生新的特性。本发明的基因递送系统，一方面能利用免疫细胞的特异性，实现对靶细胞如肿瘤细胞的杀伤；另一方面，通过对靶细胞的基因递送，进而改造病灶中细胞的基因，从而实现对靶细胞的直接杀伤。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN201980083940.2A 2018-12-17 2019-12-16 一种在细胞中递送基因的方法 Active CN113226336B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018115416319 2018-12-17
CN201811541631 2018-12-17
PCT/CN2019/125565 WO2020125576A1 (zh) 2018-12-17 2019-12-16 一种在细胞中递送基因的方法

Publications (2)

Publication Number Publication Date
CN113226336A true CN113226336A (zh) 2021-08-06
CN113226336B CN113226336B (zh) 2024-03-15

Family

ID=71101988

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980083940.2A Active CN113226336B (zh) 2018-12-17 2019-12-16 一种在细胞中递送基因的方法

Country Status (4)

Country Link
US (1) US20220056479A1 (zh)
EP (1) EP3912629A4 (zh)
CN (1) CN113226336B (zh)
WO (1) WO2020125576A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114014924A (zh) * 2021-11-17 2022-02-08 安可来(重庆)生物医药科技有限公司 一种通过brca1和bard1蛋白提高基因编辑过程中同源重组效率的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113384690B (zh) * 2021-06-21 2022-07-19 华中科技大学同济医学院附属协和医院 靶向肿瘤的体内原位诱导car-t细胞的递送系统及其应用
WO2024240006A1 (zh) * 2023-05-19 2024-11-28 粤港澳大湾区精准医学研究院(广州) 一种递送基因或治疗药物的细胞及其用途
CN118703573A (zh) * 2024-05-31 2024-09-27 福州大学 一种基于慢病毒构建多顺反子过表达载体提高外泌体产量的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074910A (zh) * 2014-08-17 2017-08-18 塞里维瑞疗法公司 改进细胞透性的高级大分子转导域（aMTD）序列、编码其的多核苷酸、鉴定包含其的aMTD的独特特征的方法、开发包含其的aMTD序列的方法
CN107530436A (zh) * 2015-01-21 2018-01-02 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
WO2018031762A1 (en) * 2016-08-10 2018-02-15 Duke University Compositions, systems and methods for programming immune cell function through targeted gene regulation
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN108243607A (zh) * 2015-09-09 2018-07-03 西雅图儿童医院（Dba西雅图儿童研究所） 用于免疫疗法的巨噬细胞的遗传工程
CN108699557A (zh) * 2015-12-04 2018-10-23 诺华股份有限公司 用于免疫肿瘤学的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532079A4 (en) * 2016-10-27 2020-07-08 Intima Bioscience, Inc. VIRAL T-LYMPHOCYTE THERAPY METHODS
CN110914289B (zh) * 2017-05-12 2024-05-14 克里斯珀医疗股份公司 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
CN108315305B (zh) * 2017-12-26 2020-11-06 沣潮医药科技（上海）有限公司 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074910A (zh) * 2014-08-17 2017-08-18 塞里维瑞疗法公司 改进细胞透性的高级大分子转导域（aMTD）序列、编码其的多核苷酸、鉴定包含其的aMTD的独特特征的方法、开发包含其的aMTD序列的方法
CN107530436A (zh) * 2015-01-21 2018-01-02 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
CN108243607A (zh) * 2015-09-09 2018-07-03 西雅图儿童医院（Dba西雅图儿童研究所） 用于免疫疗法的巨噬细胞的遗传工程
CN108699557A (zh) * 2015-12-04 2018-10-23 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
WO2018031762A1 (en) * 2016-08-10 2018-02-15 Duke University Compositions, systems and methods for programming immune cell function through targeted gene regulation
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张灿等: "以细胞为载体的药物递送系统研究进展", 中国新药杂志, vol. 23, no. 16, pages 1894 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114014924A (zh) * 2021-11-17 2022-02-08 安可来(重庆)生物医药科技有限公司 一种通过brca1和bard1蛋白提高基因编辑过程中同源重组效率的方法

Also Published As

Publication number Publication date
EP3912629A4 (en) 2022-10-12
US20220056479A1 (en) 2022-02-24
WO2020125576A1 (zh) 2020-06-25
CN113226336B (zh) 2024-03-15
EP3912629A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
US20250223584A2 (en) Compositions and methods for efficient in vivo delivery
US10988777B2 (en) Method for inducing CCR5Δ32 deletion by using CRISPR-Cas9 genome editing technique
EP3555273B1 (en) ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
CN113226336B (zh) 一种在细胞中递送基因的方法
CN106801056A (zh) 一种sgRNA及其构建的慢病毒载体和应用
CN111206032A (zh) 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
CN109097402B (zh) 一种重组载体CAR-CD244-antiCD19的制备方法
KR20210102309A (ko) 유전적으로-변형된 세포를 제작하는 줄어든, 그리고 최소한의 조작
US20250136950A1 (en) Compositions and methods for efficient in vivo delivery
CN112673094A (zh) 病毒载体产生
WO2021082784A1 (zh) 一种基于腺病毒的基因编辑方法
US12419915B2 (en) Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
CN114540309A (zh) 一种用于高效扩增rna病毒的重组细胞及其扩增方法和应用
CN114540422A (zh) 靶向受损部位递送rna药物的间充质干细胞外泌体的制备与应用
US20210254068A1 (en) Genome engineering primary monocytes
HK40048135A (zh) 一种在细胞中递送基因的方法
Cunningham Non-viral gold nanoparticle mediated delivery of CRISPR-Cas9 ribonucleoprotein and long DNA transgenes into primary blood cells
HK40048135B (zh) 一种在细胞中递送基因的方法
HK40056419A (zh) 一种在细胞中递送基因的方法
AU2022232622A1 (en) Strategies for knock-ins at c3 safe harbor sites
Freen-van Heeren Exploiting HIV-1 tropism to target CD4+ T cells for CRISPR
WO2012086702A1 (ja) 遺伝子導入方法
CN117625546A (zh) 一种提高t细胞效能的方法
WO2023140349A1 (ja) 細胞シート
KR20250141243A (ko) 데그론 융합 단백질 및 그의 생산 및 사용 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048135

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant